VBL Therapeutics to Report First Quarter 2022 Financial Results on May 17

Rhea-AI Summary

VBL Therapeutics (Nasdaq: VBLT) will announce its first-quarter financial results for the period ending March 31, 2022, on May 17, 2022, before market opening. A conference call is scheduled for 8:30 AM ET, led by CEO Professor Dror Harats and CFO Sam Backenroth, to review results and provide corporate updates. VBL is focused on developing innovative therapies for challenging malignant tumors and inflammatory conditions, with its lead candidate, ofra-vec, in a Phase 3 trial for platinum-resistant ovarian cancer.

Positive

• Upcoming release of first-quarter financial results may provide insights into future growth.
• Lead product candidate, ofra-vec, shows promise in treating platinum-resistant ovarian cancer.

Negative

• None.

TEL AVIV, Israel and NEW YORK, May 10, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that it will release first quarter financial results for the period ended March 31, 2022 on Tuesday, May 17 before market open. Professor Dror Harats, M.D, Chief Executive Officer, and Sam Backenroth, Chief Financial Officer, will host a conference call at 8:30am ET to discuss the results and provide a corporate update.

Call Details:

Tuesday, May 17, 2022 at 8:30am ET

Conference ID: 13729281

US: 1-877-407-9208

Israel Local: 1 809 406 247

International: 1-201-493-6784

Webcast:  https://edge.media-server.com/mmc/p/8pjhkd83

About VBL Therapeutics
Vascular Biogenics Ltd., operating as VBL Therapeutics (VBL), is a late-clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class treatments for difficult-to-treat malignant solid tumors and immune or inflammatory indications. VBL’s novel VTS™ gene-based platform and antibody-based monocyte targeting technology enable the creation of a pipeline of programs that are designed to harness the body’s innate biological processes to provide unique solutions for significant unmet medical needs. VBL’s lead oncology product candidate, ofra-vec (ofranergene obadenovec; `VB-111`), is an investigational targeted anti-cancer gene-based agent in development to treat a wide range of solid tumors. Ofra-vec is currently being studied in a Phase 3 registration-enabling clinical trial (NCT03398655) for platinum-resistant ovarian cancer. To learn more about VBL, please visit vblrx.com or follow VBL on LinkedIn, Twitter, YouTube or Facebook.

CONTACT
Daniel Ferry
LifeSci Advisors
+1 (617) 430-7576
daniel@lifesciadvisors.com

FAQ

When will VBL Therapeutics release its first quarter financial results?

VBL Therapeutics will release its first quarter financial results on May 17, 2022.

What time is the VBL Therapeutics conference call scheduled?

The conference call is scheduled for 8:30 AM ET on May 17, 2022.

What is the lead product candidate of VBL Therapeutics?

The lead product candidate of VBL Therapeutics is ofra-vec, an investigational anti-cancer gene-based agent.

What is the focus of VBL Therapeutics?

VBL Therapeutics focuses on developing first-in-class treatments for difficult-to-treat malignant solid tumors and immune or inflammatory indications.